Tunitas Therapeutics has won a small business innovation research (SBIR) phase II grant worth $3m from the National Institute of Allergy and Infectious Disease (NIAID) to advance asthma program.
Subscribe to our email newsletter
Aimed at advancing the company’s first clinical candidate into preclinical studies, the three-year grant will particularly support non-human primate efficacy studies, mechanism of action experiments, and discovery of a next-generation molecule.
Tunitas president and chief executive officer Nolan Sigal said, "Starting with the ground-breaking work of Dr. Andrew Saxon, Tunitas’ co-founder and Emeritus Professor at the UCLA-Geffen School of Medicine, we have successfully advanced the GE2 Program to the point where we expect to begin human clinical trials in 2014."
Designed for long-term subcutaneous therapy, the compound is a member of the GE2 family and is the fusion protein with dual mechanism.
Suppressing the production of allergic antibodies through its interaction with IgE-producing lymphocytes, GE2 directly inhibits basophil and mast cell function, the primary cellular mediators of allergic disease.